Resources | Biofidelity

Case Studies

Challenges in molecular testing: overcoming sample limitations in NSCLC

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

Case Studies

Assessing NGS: Pleural fluid cell block with limited tumor content and NGS challenges

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

Blog Posts

Beyond ALK & EGFR: Shifting the treatment paradigm of early-stage NSCLC

A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage NSCLC patients from receiving molecular profiling.

Videos

Aspyre Lung workflow

See the workflow for Aspyre Lung in the video below.

Videos

Aspyre Clinical Test workflow

See the workflow for Aspyre Clinical Test in the video below.

Product Information

Aspyre Lung product information

Fast, simple, decentralized testing for NSCLC biomarkers.

Product Information

Aspyre Clinical Test product information

Simple, fast, reliable detection of NSCLC biomarkers from tissue or blood within 2 days.

Blog Posts

ASCO 2024 workshop seeks to answer a burning question

Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from an ASCO 2024 workshop seeking to answer a burning question.

Blog Posts

Aspyre Clinical Test overcomes Next Gen Sequencing challenges with QC failures, QNS, turnaround time and cost

Learn more about how Aspyre Clinical Test for Lung overcomes your challenges with QC failures, QNS, and rapid turnaround time.

Blog Posts

Biofidelity attains ISO 13485 certification

Our certificate has been awarded for the design and development of reagents and consumables for use with in vitro diagnostic assays for molecular testing.

Blog Posts

Introducing Aspyre Clinical Test: A breakthrough in lung cancer testing

Discover Aspyre Clinical Test, a breakthrough in lung cancer testing. Our technology provides physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.

Blog Posts

Biomarker and sequential testing in early stages of NSCLC are emerging testing paradigms

Learn about the emerging trends in biomarker testing for early-stage non-small cell lung cancer (NSCLC) and the impact of minimal residual disease (MRD) testing.

Blog Posts

Good enough?

The 2023 ASCO meeting showcased impressive clinical advances in cancer treatment, but a study on liquid biopsy technology raises questions about false positive results and clinical management. Is this good enough for patients?

Blog Posts

Complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care

Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from ASCO 2023 on how the complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care.

Blog Posts

National DNA Day and the power of science

Read about what DNA Day means to Biofidelity in this blog post from our Co-founder & CEO.

Blog Posts

Closing the huge gaps in cancer treatment

Read about Crystal Cuadra-Cutler's diagnosis of non-small cell lung cancer (NSCLC) and how important biomarker testing was in her recovery.

Resource Center

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage NSCLC patients from receiving molecular profiling.

See the workflow for Aspyre Lung in the video below.

See the workflow for Aspyre Clinical Test in the video below.

Fast, simple, decentralized testing for NSCLC biomarkers.

Simple, fast, reliable detection of NSCLC biomarkers from tissue or blood within 2 days.

Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from an ASCO 2024 workshop seeking to answer a burning question.

Learn more about how Aspyre Clinical Test for Lung overcomes your challenges with QC failures, QNS, and rapid turnaround time.

Our certificate has been awarded for the design and development of reagents and consumables for use with in vitro diagnostic assays for molecular testing.

Discover Aspyre Clinical Test, a breakthrough in lung cancer testing. Our technology provides physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.

Learn about the emerging trends in biomarker testing for early-stage non-small cell lung cancer (NSCLC) and the impact of minimal residual disease (MRD) testing.

The 2023 ASCO meeting showcased impressive clinical advances in cancer treatment, but a study on liquid biopsy technology raises questions about false positive results and clinical management. Is this good enough for patients?

Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from ASCO 2023 on how the complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care.

Read about what DNA Day means to Biofidelity in this blog post from our Co-founder & CEO.

Read about Crystal Cuadra-Cutler's diagnosis of non-small cell lung cancer (NSCLC) and how important biomarker testing was in her recovery.

Sorry, your search returned no results.